S.A.R. Gardezi ( Department of Surgery, Unit 1, ICE. Medical College, North Surgical Unit, Mayo Hospital, Lahore. )
Abdul Majeed Chaudhry ( Department of Surgery, Unit 1, ICE. Medical College, North Surgical Unit, Mayo Hospital, Lahore. )
Ghulam Akbar Khan Sial ( Department of Surgery, Unit 1, ICE. Medical College, North Surgical Unit, Mayo Hospital, Lahore. )
Ijaz Ahmad ( Department of Surgery, Unit 1, ICE. Medical College, North Surgical Unit, Mayo Hospital, Lahore. )
Azam Yousuf ( Department of Surgery, Unit 1, ICE. Medical College, North Surgical Unit, Mayo Hospital, Lahore. )
Minocycline HCL was tried in 100 patients with urinary tract infections. It was highly effective in patients with E. coli and Strep faecalis infections. A convenient dose schedule, low recurrence and relatively low cost make it attractive in terms of patient compliance(JPMA 33 : 294, 1983).
The treatment of urinary tract infections is a difficult problem. One attack of UTI predisposes to a relapse or reinfection which then continues as a viscious circle. Apart from high urine output, change in the urinary pH, and removal of the precipitating cause, the main aim of the treatment is the administration of a suitable antimicrobial (Kitamoto et al., 1969). In this study efficacy of Minocydline a Semisynthetic derivative of Tetracycline in UTI was studied.
Material and Methods
The patients, included in this trial had established urinary tract infection. Sixty five were selected from North Surgical Unit, twenty from outpatient department and fifteen from the emergency room. They were divided into two groups (Table I).
Group ‘A’ consisted of 50 patients who underwent a surgical procedure. Remaining 50 patients (Group ‘B’) were treated conservatively. Of these 35 patients were treated as outpatients and 15 were hospitalised. Urinilysis, urine culture and sensitivity, complete blood count, blood urea and blood sugar were done in all the cases. Radiological investigations were done only when indicated.
Children below 8 years, pregnant females and diabetics were excluded from the trial. Minocycline HCL was administrated orally or parenterally. Initial dose of 200 mg was followed by 100mg twice a day for 5-7 days in group ‘A’ and 10-15 days in Group ‘B’ depending upon the response in individual cases.
Minocycline was introduced as a semisynthetic derivative of Tetracycline in 1967 internationally and 1976 in Pakistan. Its chemical name is "7-dimethyl amino-6-deoxy-demethyl tetracycline". It belongs to the group known as "Polycyclic naphtahacane carboxamides" (Martell and Booth, 1967).
Minocycline HCL is rapidly absorbed after oral administration. Unlike most tetracyclines, its absorption is not significantly impaired by ingestion of food or milk (Haine, 1969). After single oral dose of 150mg minocycline HCL gives serum levels which are 2-4 times .higher than other tetracyclines. After 24hours serum level of Minocycline HCL (150mg) may be as high as 16 times than other tetracyclines (250mg) (Kanazawa and Kuamata, 1969). Its serum half life is 18 hours (Fedorko et al., 1968). Seventy percent of the drug is protein bound (Ory, 1970). Some drug is still detectable in the serum upto 96 hours after single oral dose. It is because the protein bound portion is gradually released and becomes active (MacDonald et al., 1973).
Minocycline HCL is widely distributed in body tissues (Colaizzi and Klink, 1969). Because of its high lipophffic properties it penetrates the epithelial membrane of the prostate in high concentrations (Brannan, 1975). Minocycline HCL is excreted partly through the kidney and partly through liver (Steigbigel et al., 1968). One third to half of the drug can be recovered from these cources, rest of the drug is metabolized in the liver (Bernard et al., 1971). A small percentage gets incorporated in the developing teeth and bone (Grossman et al., 1971).
Minocycline HCL like other tetracyclines acts by interfering with nucleic acid metabolism and protein synthesis of bacteria (Swenson and Sanford, 1970).
Minimum inhibitory concentration of Minocycline HCL in serum is 1-3 microgram/mI. With usual dosage the level obtained is between 2-5 microgram/mI. It has wide margin of safety because the toxic effects appear at about 40-50 microgram/mi (Redin, 1967).
The value of Minocycline HCL in the treatment of urinary tract infections has been established in a number of trials (Steigbigel et al., 1968; Nakazawa et al., 1969; Frisk and
Tunevall, 1969; Ronald et al., 1968). Of various antibiotics tested in the trial, Minocycline HCL was found to be most effective in E. coliC and Strep faecalis infections. Its efficacy against more resistant urinary pathogens like Pseudomonas, Kiebsiella, Proteus and Gonococci was comparable to other commonly used antibiotics. Infrequent adverse reactions, economy and convenience of dosage were responsible for higher patient compliance. In patients where oral therapy was not possible in early stages its availability in injectable form was found to be an added advantage.
Majority of our patients do not return for follow-up and repeated culture and sensitivity studies are not possible due to various economic and human factors. The use of an antimicrobial with low recurrence rate of infectiOn is therefore welcome to eradicate this potentially lethal disease (Carrol et al., 1970).
Minocydline HCL with its effectiveness against E.coli infections, convenient dosage schedule and low recurrence rate of infection is likely to attain a certain place in the therapy of urinary tract infections.
The authors are grateful to Prof. Zafar-ulAziz, D. Bact. (London), F.R.C. Path., F.I.C.P., formerly of the Department of Pathology, K.E. Medical College for arranging culture and sensitivity studies for the trial. We are deeply appreciative of the help afforded by Dr. S.N.H. Kazmi (Medical Officer), Dr. Masood Rashid (Medical Officer), Dr. Nasim Osmani Roohi, Dr. Capt. Abdul Khaliq, Dr. Najam Asif, Dr. Gulraiz Rauf and Mr. Nayyar Saleem in conducting this study. Thanks are also due to Mr. Abdul Ghaffar Naeem of the Postgraduate Medical Institute, Lahore, for typing this article.
1. Bernard, B., Yin, EJ. and Simon, H.J. (1971) Clinical pharmacologic studies with minocycline. J. Clin. PharmacoL, 11:332.
2. Brannan, W. (1975) Treatment of chronic Prostatitis; Comparison of minocycline and doxycycline Urology, 5:726.
3. Carrol, G., Cambell, M.F., and Harrison, J.H. Urology, Vol. 1. Philadelphia, Saunders, 1970, pp.404-5.
4. Colaizzi, J.L. and Klink, P.R. (1969) pH-partition behaviour of tetracyclines. J. Pharn. Sci., 58:1184.
5. Fedorko, J., Katz, S. and Al]noch, H. (1968) In vitro activity of minocycline, a new tetracycline. Am. J. Med. ScL, 255:25 2.
6. Frisk, A.R. and Tunevall, G. (1969) Clinical evaluation of minocycline. Antimicrob. Agents Chemother., 8:335.
7. Grossman, E.E., Waichak, A. and Freedman, H. (1971) Tetracyclines and permanent teeth; the relation between the dose and tooth color. Paediatrics, 47:576.
8. Haine, K.P. A study of certain pharmacokinetic properties of a new tetracycline derivative minocydline. Zurich, University of Zurich, 1969.
9. Kanazawa, Y. and Kuramata, T. (1969) Estimation of minocycline concentration in body fluids and sensitivity tests by a disc method. Jap. 3. Antibiot., 22 :417.
10. Kitarnoto, 0., Fukaya, K. and Tomori, G. (1969) Pharmacodynamics of antimicrobial agents on 7-dimethylamino6-deoxy-6-demethyl-tetracycline (monocycline). Jap. J. Antibiot., 22 :435.
11. MacDonald, H., Kelly, R.G., Allen, E.S., Noble, J.F. and Kanegis, L.A. (1973) Pharmacokinetic studies on minocycline in man. Clin. Pharmacol. Ther., 14:852.
12. Martell, MJ. Jr. and Booth, J.H. (1967) The 6-deoxytetracyclines. VII. Alkylated aminotetracyclines possessing unique antibacterial activity. J. Med. Chem., 10:44.
13. Nakazawa, S., Ono, H., Nishino, T., Kuwabara, S. and Goto, S. (1969) in vitro and in vivo laboratory evaluation of Minocycline. Prog. Antimicrob. and Anticancer Chemother. 6th internal. Congr. Chemother. Tokyo, 1:353.
14. Ory, E.M. (1970) The Tetracyclines. Med. Clin. N. Am.,, 54:1173.
15. Redin, G.S. (1967) Antibacterial activity in mice of minocycline, a new tetracycline. Antimicrob. Agents Chemother., 6:371.
16. Ronald, A.R., Eby, 3. and Sherris, J.C. (1968) Susceptibility of Neisseria gonorrhoeae to penicillin and tetracycline. Antimicrob. Agents Chemother., 8:431.
17. Steigbigel, N.H., Reed, C.W. and Finland, M. (1968) Absorption and excretion of five tetracycline analogues in normal young men. Am. 3. Med. Sci., 255:296.
18. Steigbigel N.H., Reed, C.W. and Finland, M. (1968) Susceptibility of common pathogenic bacteria to seven tetracycline antibiotics in vitro. Am. J. Med. Sci., 255:179.
19. Swenson, R.M. and Sanford, J.P. (1970) Clinical implications of the mechanism of action of antimicrobial agents. Adv. Intern. Med., 16:373.